Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Leap Therapeutics, Inc. LPTX
$0.43
+$0 (0.78%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
50033209.00000000
-
week52high
1.86
-
week52low
0.27
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.74359800
-
EPS
-0.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 15 авг 2022 г. |
| Raymond James | Outperform | Outperform | 13 июл 2022 г. |
| Mizuho | Buy | 04 окт 2021 г. | |
| Raymond James | Outperform | Outperform | 14 сент 2021 г. |
| Raymond James | Outperform | Outperform | 02 мар 2021 г. |
| Raymond James | Outperform | Outperform | 11 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 янв 2023 г. |
| Mizuho | Buy | Buy | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Schilsky Richard | A | 100000 | 100000 | 06 сент 2022 г. |
| CAVANAUGH JAMES H | A | 25000 | 25000 | 01 сент 2022 г. |
| Granfield Christine | A | 200000 | 200000 | 01 сент 2022 г. |
| Sirard Cynthia | A | 200000 | 200000 | 01 сент 2022 г. |
| O'Mahony John Mark | A | 200000 | 200000 | 01 сент 2022 г. |
| ONSI DOUGLAS E | A | 200000 | 200000 | 01 сент 2022 г. |
| Mirabelli Christopher | A | 200000 | 200000 | 01 сент 2022 г. |
| LAWLOR AUGUSTINE | A | 200000 | 200000 | 01 сент 2022 г. |
| LI WILLIAM | A | 25000 | 25000 | 01 сент 2022 г. |
| Dietz Thomas John | A | 30000 | 30000 | 01 сент 2022 г. |
Новостная лента
Mergers and Acquisitions in 2023 Off To A Strong Start
MarketBeat
27 янв 2023 г. в 08:17
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
PRNewsWire
07 ноя 2022 г. в 08:05
55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical trial CAMBRIDGE, Mass. , Nov. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in second-line gastroesophageal adenocarcinoma (GEA) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022.
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
PRNewsWire
05 окт 2022 г. в 08:05
CAMBRIDGE, Mass. , Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in second-line gastroesophageal junction/gastric (GEJ/G) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022.
Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress
PRNewsWire
04 сент 2022 г. в 18:05
Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups Median Overall Survival is not mature with only 44% of patients deceased as of the data cut Enrollment ongoing in the study of DKN-01 plus Tecentriq® (atezolizumab) in second- or third-line oesophagogastric cancer patients, activity in DKK1-high patients consistent with prior studies with pembrolizumab or tislelizumab CAMBRIDGE, Mass. , Sept. 4, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma (GEA) from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology (ESMO) Congress 2022 being held on September 9-12.